FDA’s 2025 regulatory shift: integrating sex-specific data across the medical device lifecycle

1. Understanding the FDA’s three guiding documents

In early 2025, the FDA published three foundational documents to create a consistent framework that includes sex-specific data principles with actionable, enforceable guidelines for manufacturers, offering a comprehensive roadmap for compliance. These documents and their implications will be addressed below.

1. Final Guidance (March 2025): Evaluation of Sex-Specific Data in Medical Device Clinical Studies – Link
2. Final Information Sheet (January 2025): Evaluation of Sex Differences in Clinical Investigations – Link
3. Draft Guidance (January 2025): Study of Sex Differences in the Clinical Evaluation of Medical Products – Link

With these three documents, the FDA presents not only the science of today but also an industry blueprint for the future, where sex-based clinical differences are key levers for public trust and innovation.

The interplay of these publications will guide study sponsors in aligning their clinical trials and post-market plans with the FDA’s evolving expectations. Understanding this alignment will make it easier for manufacturers to approach the expanded regulatory landscape.

1.1. FDA final guidance (March 2025): Evaluation of sex-specific data in medical device clinical studies 

Medical devices must work safely and effectively for everyone, women and men alike. However, biological differences (such as size, hormone levels, and organ function) can impact how devices perform across sexes.

Historically, women have often been underrepresented in clinical studies. As a result, there has been less data available on how devices affect women compared to men, leading to potential risks.

In response, the FDA issued the “Evaluation of Sex-Specific Data in Medical Device Clinical Studies” Final Guidance, outlining clear recommendations for manufacturers to:

• Enroll adequate numbers of both women and men,
• Analyze data by sex, and,
• Report sex-specific outcomes transparently.

This guidance is relevant for devices that require clinical information as part of FDA marketing submissions. Such submissions include Premarket Notifications (510(k)), Premarket Approvals (PMA), De Novo Requests, and Humanitarian Device Exemptions (HDE). Additionally, the scope extends to post-market studies, like Post-Approval Studies (PAS) and Post-Market Surveillance (522 studies). It is worth noting that some devices, such as pregnancy tests or sex-specific implants, inherently apply to only one sex.

1.2. Key expectations for manufacturers

From the outset, manufacturers are advised to factor in sex differences in their planning and implementation of device development and studies. The following points should be considered:

• Considering Sex Differences from the Start: Manufacturers should evaluate whether biological sex has an impact on disease prevalence, diagnosis, treatment, or outcomes. Sex-specific risks and benefits should be carefully documented in study protocols. Additionally, investigators must receive training to better understand sex differences and promote balanced enrollment during clinical studies.
• Planning for Representative Enrollment: Clinical studies should aim for an enrollment that accurately reflects the demographics of the disease being studied. For instance, if 55% of affected individuals are women, then 55% of study participants should also be women. Manufacturers should ensure that eligibility criteria are free of unnecessary restrictions that might disproportionately exclude one sex, such as body size limitations.
• Designing Clinical Studies Thoughtfully: Clinical study designs should include sex as a stratification factor in randomization processes. Researchers should analyze whether device performance varies between sexes. Even when no differences are anticipated, manufacturers should plan for sex-specific statistical analyses.
• Analyzing and Interpreting Sex-Specific Data: Statistical analyses should be performed to identify any meaningful differences in device performance between women and men. If differences are observed, these should be examined further to determine whether they stem from factors such as body size or comorbidities. Even in cases where the sample size for one sex group is small, these findings must still be reported.
• Reporting Sex-Specific Results Transparently: Manufacturers should ensure sex-specific results are clearly documented. This includes providing detailed data on enrollment numbers, baseline characteristics, as well as safety and effectiveness outcomes for each sex. Such results should be included in public documents, such as device labeling, 510(k) summaries, and PMA summaries.
• Increasing Female Enrollment: Manufacturers are encouraged to take proactive steps to ensure balanced enrollment in clinical trials. This can include targeting diverse clinical sites, such as women’s health clinics, and making communications and consent forms more engaging for women. Practical support measures, like flexible scheduling, childcare support, or transportation compensation, can further encourage participation. Additionally, manufacturers should monitor enrollment and adjust strategies if they observe that women’s participation lags during the trial.
• Special Considerations for Diagnostics: For diagnostic devices, such as in vitro diagnostics (IVDs) or imaging devices, manufacturers should include specimens from both men and women while establishing cutoffs and validating performance. In cases where it is clinically justified, manufacturers should also consider the use of separate reference ranges for men and women.
• Post-market Expectations: When sex-specific differences are identified after a device has received marketing approval, manufacturers must update the product labeling accordingly. If necessary, additional post-market studies should be conducted to fully understand the sex-based effects of the device.

The March 2025 FDA Final Guidance establishes stringent requirements for sex-specific data evaluation in device studies. By following this guidance, manufacturers help ensure their devices serve all patients — men and women — more effectively and safely. However, to fully align with these expectations, manufacturers must also adopt ethical principles outlined in the January 2025 Final Information Sheet. 

1.3. January 2025 information sheet – Why it still matters for device studies

While the January 2025 Information Sheet is not specifically designed for medical device manufacturers, the ethical principles it outlines remain highly relevant and applicable to device trials.

Clinical trial involving female participants of childbearing potential, or that raise questions about reproductive risk and informed consent, must carefully take the ethical principles in the Information Sheet into consideration.
Understanding these expectations can help manufacturers align protocols and avoid unnecessary Institutional Review Board (IRB) pushback.

The key takeaways for medical device sponsors are summarized below, detailing how they complement the March 2025 Device-Specific Final Guidance, and highlighting three key ethical lessons from the Information Sheet that sponsors should consider incorporating into their clinical trial practices.

• Don’t exclude women without justification: The FDA emphasizes enrolling women, including those of childbearing potential, in early-phase studies — using appropriate safeguards rather than exclusion. For device trials, this aligns with the March 2025 FDA guidance calling for representative enrollment and ethical study design.

• Inform and protect through better consent processes: When reproductive toxicity data are incomplete (as they could be in early device studies), investigators are expected to inform participants about potential risks and update consent forms as new data become available.

For device sponsors, this means your informed consent forms should be explicit, evolving, and IRB-aligned — especially when the device interacts with reproductive anatomy or function.

• Anticipate IRB expectations shaped by this document: Even though this sheet is not device-specific, IRBs may adopt its principles across the board.
  Expect more scrutiny on:
  • Sex-balanced enrollment plansRisk-benefit profiles for women
  • Transparent reproductive health disclosures

The January 2025 FDA Information Sheet serves as an essential complement to the March 2025 Final Guidance by outlining ethical principles critical to fostering inclusive and balanced clinical trials.

By implementing these lessons, manufacturers can address IRB concerns, strengthen trial protocols, and reduce risks associated with sex-based data gaps.

1.4. January 2025 draft guidance – Expanding expectations

The January 2025 Draft Guidance expands the scope of sex-specific data evaluation across the entire medical device lifecycle. Together with the Final Guidance and Information Sheet, the Draft Guidance completes the picture of FDA’s evolving standards for ensuring scientific rigor, balanced sex representation, and patient trust. It introduces expanded recommendationson enrollment, data analysis, reporting, and post-market evaluation.

The below side-by-side comparison of all 3 relevant documents maps the requirements to a theme and phase of the device lifecycle and facilitates gap assessments and cross-functional planning across Regulatory, Clinical, and Quality Management teams.

* Each row corresponds to a key theme in the medical device lifecycle, with referenced citations from each FDA document.

2. Business implications for manufacturers: challenges and opportunities

The FDA’s 2025 regulatory framework presents significant business implications for medical device manufacturers. By requiring the integration of sex-specific data across the device lifecycle, the new regulations necessitate adjustments to manufacturers’ research methodologies, resource allocation, and overall operations.

Challenges facing manufacturers include increased R&D costs and timeframes, as well as operational restructuring and training. Manufacturer clinical trials will require comprehensive sex-stratified analyses, leading to increased costs in research and development. Expanding enrollment criteria to achieve sex-balanced representation may also extend study timelines, necessitating revised budgeting and strategic planning.

Furthermore, compliance with the above guidelines will demand enhanced capabilities in regulatory affairs, clinical study design, and data collection. Teams may require specialized training in the latest methodologies for sex-stratified data analysis, as informed by the January and March 2025 FDA documents. Organizations will need to establish cross-functional processes to ensure alignment with ethical expectations and IRB requirements.

However, the incorporation of sex-specific safety and regulatory compliance can also offer opportunities for manufacturers to enhance market trust and transparency and drive innovation. Devices aligned with these regulatory standards may experience improved consumer confidence, bolstering market acceptance and mitigating reputational risks associated with noncompliance.

Integrating sex-based considerations fosters a deeper understanding of device performance, prompting advancements in personalized medical solutions. This strategic approach can open doors to novel product lines designed to meet diverse demographic needs.

The FDA’s 2025 regulatory shift compels manufacturers to adopt rigorous practices that prioritize inclusivity and precision in medical device development. Although implementation comes with heightened operational demands, proactive adaptation may yield substantial benefits, including stronger stakeholder rapport, enhanced public trust, and avenues for innovative growth in a competitive market landscape.

3. Conclusion

The release of the FDA’s Final Guidance in March 2025 for medical device clinical studies represents only one piece of a broader regulatory framework aimed at embedding sex-specific considerations across the lifecycle of medical products. This paradigm shift is reinforced by two supporting documents introduced earlier in the year — the January 2025 Final Information Sheet and the January 2025 Draft Guidance.
Together, these three publications establish a cohesive set of principles and requirements for evaluating sex differences in research methodologies, reporting processes, and post-market accountability.

Manufacturers must integrate these FDA requirements to ensure compliance, align with evolving regulatory standards, and demonstrate their commitment to scientific rigor, fair sex representation, and public health.

Need help?

Contact our team of regulatory experts at technicaldivision@efor-group.com for support with the following:

• Gap analysis to determine compliance of your devices and studies with the above requirements
• Hotline support for quick responses to your questions; Clinical Audits via our certified Auditors
• Distance-based or e-learning modules to train your teams on the latest regulatory developments via our certified Training Center TREE